Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 24 · below the Ichimoku cloud · RSI 16 (oversold) · MACD below its signal · 1% above its 52-week low
| Investor | Value | Of portfolio | Shares | Change | Quarter |
|---|---|---|---|---|---|
| Renaissance Technologies | $907.2K | 0.00% | 297.44K | −60% | Q2 2026 |
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a LRMR trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 28, 2026 | Harlow John B. Jr.President | Stock Award(Grant) at price 0.00 per share. | 50K | — |
| Jul 5, 2026 | Hamilton Thomas EdwardDirector | Purchase at price 3.34 per share. | 50K | $166.89K |
| Feb 26, 2026 | Sherman Jeffrey WDirector | Purchase at price 5.00 per share. | 5K | $25.00K |
| Feb 26, 2026 | Thomas Frank EDirector | Purchase at price 5.00 per share. | 5K | $25.00K |
| Feb 26, 2026 | Flynn James EDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 5.00 per share. | 5.00M | $25.00M |
| Feb 26, 2026 | Hamilton Thomas EdwardDirector | Purchase at price 5.00 per share. | 100K | $500.00K |
| Jan 25, 2026 | Ben Maimon Carole SChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 100.1K | — |
| Jan 25, 2026 | Celano MichaelChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 37.6K | — |
| Jan 25, 2026 | Clayton RussellOfficer | Stock Award(Grant) at price 0.00 per share. | 25.6K | — |
| Jan 25, 2026 | Shankar GopiOfficer | Stock Award(Grant) at price 0.00 per share. | 25.6K | — |
| Jul 30, 2025 | Flynn James EDirector and Beneficial Owner of more than 10% of a Class of Security | Purchase at price 3.20 per share. | 9.38M | $30.00M |
| Jan 21, 2025 | Ben Maimon Carole SChief Executive Officer | Stock Award(Grant) at price 0.00 per share. | 91K | — |
| Jan 21, 2025 | Celano MichaelChief Financial Officer | Stock Award(Grant) at price 0.00 per share. | 34.2K | — |
| Jan 21, 2025 | Clayton RussellOfficer | Stock Award(Grant) at price 0.00 per share. | 23.3K | — |
| Jan 21, 2025 | Shankar GopiOfficer | Stock Award(Grant) at price 0.00 per share. | 23.3K | — |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -7.1 | 50.0 | -15.3 | -9.8 | -14.3 | -12.4 | 25.2 | 0.0 | -16.4 | -32.4 | −43.3% | ||
| 2025 | -0.8 | -21.1 | -29.0 | 23.3 | -15.1 | 28.4 | 19.7 | 4.6 | -10.8 | 20.4 | -9.0 | 7.6 | −1.6% |
| 2024 | 27.3 | 98.6 | -34.0 | -9.2 | 16.1 | -9.4 | 15.7 | -5.7 | -17.2 | 25.6 | -23.0 | -38.9 | −14.9% |
| 2023 | 19.6 | 22.7 | -25.2 | 4.4 | -22.0 | -15.2 | 36.7 | -13.1 | 6.2 | -25.8 | 17.1 | 32.7 | +10.2% |
| 2022 | -10.1 | -55.1 | -7.1 | -8.4 | -30.5 | -24.0 | -8.7 | 52.0 | 17.6 | 3.1 | -3.9 | 30.3 | −61.7% |
| 2021 | -26.6 | 8.7 | -14.4 | -8.9 | -37.6 | 18.2 | 1.2 | 44.8 | -19.9 | 3.6 | -23.1 | 17.4 | −49.6% |
| 2020 | 3.6 | -0.9 | -32.5 | 4.5 | 27.3 | 4.5 | -14.4 | 11.9 | 23.2 | 23.9 | 18.2 | -3.6 | +60.7% |
| 2019 | -10.3 | 0.7 | -38.7 | -6.6 | -28.5 | -35.0 | -23.5 | -9.3 | -10.4 | 0.1 | 9.5 | 37.0 | −77.6% |
| 2018 | 48.7 | 14.4 | -5.2 | -8.9 | 4.1 | 44.7 | 1.7 | -8.5 | 22.8 | -16.9 | -48.1 | -1.8 | +7.1% |
| 2017 | 32.4 | -5.7 | 17.4 | 4.7 | -30.5 | 3.5 | -3.7 | 6.8 | -2.5 | 1.1 | 9.8 | 18.2 | +45.3% |
| 2016 | 5.7 | -5.9 | 6.7 | -4.6 | 10.8 | -15.2 | -49.2 | -1.6 | 10.7 | -9.1 | 12.3 | -5.9 | −49.4% |
| 2015 | 23.2 | 1.7 | 2.5 | -21.4 | 4.6 | 6.4 | 9.6 | -3.8 | -12.5 | -69.9 | 75.6 | -62.8 | −79.6% |
| 2014 | -11.5 | 19.7 | -6.2 | 8.4 | 10.8 | 30.6 | +55.9% |
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal disease. The company is based in Bala Cynwyd, Pennsylvania.
Buy / hold / sell counts